Global Hydronephrosis Market – Industry Trends and Forecast to 2031

Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

Global Hydronephrosis Market – Industry Trends and Forecast to 2031

  • Healthcare
  • Upcoming Reports
  • Jul 2024
  • Global
  • 350 Seiten
  • Anzahl der Tabellen: 60
  • Anzahl der Abbildungen: 220

Global Hydronephrosis Market

Marktgröße in Milliarden USD

CAGR :  % Diagram

Diagramm Prognosezeitraum
2024 –2031
Diagramm Marktgröße (Basisjahr)
USD 3.22 Billion
Diagramm Marktgröße (Prognosejahr)
USD 6.72 Billion
Diagramm CAGR
%
Diagramm Wichtige Marktteilnehmer
  • Allergan (Ireland)
  • Amgen Inc. (U.S.)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)

Global Hydronephrosis Market, By Indication (Intrinsic and Extrinsic), Treatment (Shock Wave Lithotripsy, Laparoscopy, Bladder Catheterization, Steroid Therapy, and Others), Type (Unilateral and Bilateral), Diagnosis (Laboratory Test and Imaging) – Industry Trends and Forecast to 2031.

Hydronephrosis Market

Hydronephrosis Market Analysis and Size

The global hydronephrosis market is experiencing growth driven by increasing awareness, advancements in medical technology, and rising incidences of urinary tract obstructions. Hydronephrosis, characterized by kidney swelling due to urine build-up, affects a significant number of individuals globally, with varying causes including kidney stones, tumors, or congenital abnormalities. The market's expansion is also propelled by diagnostic innovations such as ultrasound, CT scans, and MRI, facilitating early detection and treatment planning. Additionally, surgical interventions like ureteral stenting and nephrostomy are key treatments, ensuring relief from symptoms and preserving kidney function.

Global hydronephrosis market size was valued at USD 3.22 billion in 2023 and is projected to reach USD 6.72 billion by 2031, with a CAGR of 9.64% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016-2021)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Indication (Intrinsic and Extrinsic), Treatment (Shock Wave Lithotripsy, Laparoscopy, Bladder Catheterization, Steroid Therapy, and Others), Type (Unilateral and Bilateral), Diagnosis (Laboratory Test and Imaging)

Countries Covered

U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America

Market Players Covered

Allergan (Ireland), Amgen Inc. (U.S.), Sanofi (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Boston Scientific Corporation (U.S.), B. Braun Melsungen AG (Germany), Stryker (U.S.), Zimmer Biomet (U.S.), Smith & Nephew plc (U.K.), Promega Corporation (U.S.), Sigma-Aldrich Co. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.)

Market Opportunities

  • Rising Healthcare Expenditure
  • Advancements in Treatment Options for Hydronephrosis  

Market Definition

Hydronephrosis is a medical condition characterized by the swelling or dilation of one or both kidneys due to a buildup of urine. This occurs when there is an obstruction or blockage in the urinary tract, preventing urine from draining properly from the kidney to the bladder. The obstruction can be caused by various factors, such as kidney stones, congenital abnormalities, tumors, or scarring from previous infections.   

Hydronephrosis Market Dynamics

Drivers

  • Increasing Prevalence of Hydronephrosis   

The prevalence of hydronephrosis is steadily increasing globally, primarily due to rising incidences of urinary tract obstructions and various kidney disorders. Factors such as kidney stones, tumors, congenital anomalies, and infections contribute significantly to the development of hydronephrosis. The condition affects individuals of all ages but is particularly prevalent among adults and elderly populations. As lifestyles evolve, dietary habits change, and chronic conditions like diabetes and hypertension become more widespread, the risk factors for urinary tract complications and kidney-related disorders increase, driving the market growth.  

  • Growing Geriatric Population Prone to Kidney-Related Disorders  

The global demographic shift towards an aging population has led to a heightened susceptibility to kidney-related disorders, including hydronephrosis. Elderly individuals often experience physiological changes that affect kidney function, such as decreased renal blood flow and diminished ability to concentrate urine. These factors, coupled with the prevalence of chronic diseases like diabetes and hypertension among the elderly, contribute to an increased incidence of hydronephrosis. As the elderly population continues to grow, healthcare providers face greater demands in managing and treating kidney-related conditions effectively, driving the market growth.

Opportunities

  • Rising Healthcare Expenditure     

Recent advancements in the treatment of hydronephrosis have revolutionized patient care, offering more effective and less invasive options for management. Minimally invasive surgical procedures, such as ureteral stenting and nephrostomy, have become standard practice in relieving urinary tract obstructions and restoring kidney function. These procedures not only reduce recovery times and hospital stays but also minimize the risk of complications compared to traditional open surgeries. Moreover, pharmaceutical therapies aimed at addressing underlying causes of hydronephrosis, such as medications to dissolve kidney stones or manage infections, have improved patient outcomes significantly, creating opportunities for market growth. 

  • Advancements in Treatment Options for Hydronephrosis     

The global rise in healthcare expenditure reflects increasing investments in infrastructure, technology, and patient care, which are pivotal in addressing complex medical conditions like hydronephrosis. Governments and private sectors are allocating substantial resources towards improving healthcare accessibility and quality, particularly in developing regions where infrastructure gaps exist. This surge in funding supports the expansion of healthcare facilities, procurement of advanced medical equipment, and training of healthcare professionals specializing in kidney-related disorders. In addition, higher healthcare spending fosters research and development initiatives aimed at discovering innovative treatments and diagnostic tools for hydronephrosis.  These are creating significant market opportunities, reducing the burden of kidney-related diseases on individuals and societies alike.

Restraints/Challenges

  • Adverse Effects of Medications and Surgical Interventions 

While advancements in hydronephrosis treatment offer significant benefits, they also come with potential risks and side effects that patients and healthcare providers must consider. Medications prescribed for managing kidney stones or infections may cause adverse reactions such as gastrointestinal upset or allergic responses in some individuals. Similarly, surgical interventions like ureteral stenting or nephrostomy carry risks of complications such as infection, bleeding, or damage to surrounding tissues. These potential side effects underscore the importance of thorough risk assessment and patient counselling before initiating treatment.  

  • Regulatory Requirements for New Medical Devices and Treatments        

Navigating the regulatory landscape presents significant challenges for companies developing new medical devices and treatments for hydronephrosis. Stringent regulatory requirements, varying across different regions and countries, necessitate extensive clinical trials, safety evaluations, and documentation to obtain approvals. These processes aim to ensure the efficacy, safety, and quality of healthcare products before they reach the market and are used in patient care. However, the lengthy approval timelines and resource-intensive nature of regulatory compliance can pose barriers to innovation and market entry for smaller companies or start-ups.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In August 2023, Novartis announced the successful acquisition of Chinook Therapeutics, Inc., a biopharmaceutical company headquartered in Seattle, WA. Chinook Therapeutics specializes in the research, development, and commercialization of precision medicines targeting kidney diseases

Hydronephrosis Market Scope

The market is segmented on the basis of indication, treatment, type, and diagnosis. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Intrinsic
    • Acute Unilateral Obstructive Uropathy
    • Kidney Stone
    • Bladder Cancer
    • Bladder Stones
    • Cystocele
    • Urethral Stricture
    • Urethral Cancer
    • Others
  • Extrinsic
    • Retroperitoneal Fibrosis
    • Ovarian Vein Syndrome
    • Cancer of the Cervix
    • Cancer of the Prostate
    • Uterine Prolapse
    • Prostate Cancer
    • Pregnancy
    • Others

Treatment

  • Shock Wave Lithotripsy
  • Laparoscopy
  • Bladder Catheterization
  • Steroid Therapy
  • Others

Type

  • Unilateral Hydronephrosis
  • Bilateral Hydronephrosis

Diagnosis

  • Laboratory Test
    • Urinalysis
    • Complete Blood Count
    • Electrolyte Analysis
    • Others
  • Imaging
    • CT Scan Ultrasound
    • Intravenous
    • Pyelography
    • KUB X-Rays
    • Others

Hydronephrosis Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, indication, treatment, type, and diagnosis as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to increased expenditure on research and development, substantial healthcare spending, a higher prevalence of kidney-related disorders, the presence of key market players, and the introduction of technologically advanced products in these regions.   

Asia-Pacific is expected to witness significant growth during the forecast period due to rising government expenditure on the healthcare sector, an increasing geriatric population, especially in emerging economies like India and China, and rising personal disposable income. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Hydronephrosis Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

  • Allergan (Ireland)
  • Amgen Inc. (U.S.)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Boston Scientific Corporation (U.S.)
  • B. Braun Melsungen AG (Germany)
  • Stryker (U.S.)
  • Zimmer Biomet (U.S.)
  • Smith & Nephew plc (U.K.)
  • Promega Corporation (U.S.)
  • Sigma-Aldrich Co. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Bio-Rad Laboratories, Inc. (U.S.)


SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The market is segmented based on , By Indication (Intrinsic and Extrinsic), Treatment (Shock Wave Lithotripsy, Laparoscopy, Bladder Catheterization, Steroid Therapy, and Others), Type (Unilateral and Bilateral), Diagnosis (Laboratory Test and Imaging) – Industry Trends and Forecast to 2031. .
The Global Hydronephrosis Market size was valued at USD 3.22 USD Billion in 2023.
The Global Hydronephrosis Market is projected to grow at a CAGR of 9.64% during the forecast period of 2024 to 2031.
The major players operating in the market include Allergan (Ireland), Amgen Inc. (U.S.), Sanofi (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Boston Scientific Corporation (U.S.), B. Braun Melsungen AG (Germany), Stryker (U.S.), Zimmer Biomet (U.S.), Smith & Nephew plc (U.K.), Promega Corporation (U.S.), Sigma-Aldrich Co. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.).
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.